PRODUCT INFORMATION

H2L 5765834

Item No. 45940

CAS Registry No.: 420841-84-5
Formal Name: 2,3-dihydro-2-[3-(4-nitrophenoxy)phenyl]-1,3-dioxo-1H-isoindole-5-carboxylic acid
MF: $C_{21}H_{12}N_2O_7$
FW: 404.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

H2L 5765834 is supplied as a solid. A stock solution may be made by dissolving the H2L 5765834 in the solvent of choice, which should be purged with an inert gas. H2L 5765834 is soluble (≥10 mg/ml) in DMSO.

Description

H2L 5765834 is an antagonist of lysophosphatidic acid receptor 1 (LPA_1), LPA_3, and LPA_5 (IC_{50}s = 94, 752, and 463 nM, respectively).[1] It is selective for these receptors over LPA_2 and LPA_4. H2L 5765834 (50 µM) reverses increases in viability induced by overexpression of the gene encoding autotaxin, also known as ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (*ENPP2*), in MIN6 pancreatic β-cells.[2] It decreases mechanical hypersensitivity in an NCTC clone 2472 murine fibrosarcoma model of cancer-associated pain.[3]

References

1. Fells, J.I., Tsukahara, R., Liu, J., *et al.* Structure-based drug design identifies novel LPA_3 antagonists. *Bioorg. Med. Chem.* **17(21),** 7457-7464 (2009).
2. Zhou, Y., Zeng, Y., Chen, Y., *et al.* Phosphodiesterase ENPP2, which is co-upregulated in obese and pregnant mice, is essential for islet beta cell compensation during obesity. *Diabetologia* **69(4),** 1000-1020 (2026).
3. Khasabova, I.A., Khasabov, S.G., Johns, M., *et al.* Exosome-associated lysophosphatidic acid signaling contributes to cancer pain. *Pain* **164(12),** 2684-2695 (2023).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM